Since CYR61 has known oncogenic functions in serval tumor entities (12, 13), including breast cancer (15, 16), the question appeared if CYR61 might be a valuable therapeutic target in aggressive breast cancer and if it could be a prognostic marker for these indications. This evidence concerns the gene CCN1 and breast carcinoma.